U.S. Markets close in 4 hrs 2 mins
Stocks To Watch

Target soars on sales rebound, Urban Outfitters surges on beat, Apple eyes Hollywood

Regulus Therapeutics Inc. (RGLS)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.8800-0.0022 (-0.2494%)
As of 11:54AM EDT. Market open.
People also watch
PTCTCEMPOMEDVSTMOVAS
Full screen
Previous Close0.8822
Open0.8800
Bid0.8773 x 600
Ask0.8834 x 500
Day's Range0.8658 - 0.8960
52 Week Range0.8500 - 3.6500
Volume213,776
Avg. Volume839,239
Market Cap91.33M
Beta1.92
PE Ratio (TTM)-0.58
EPS (TTM)-1.52
Earnings DateOct 30, 2017 - Nov 3, 2017
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.94
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents3 days ago

    Edited Transcript of RGLS earnings conference call or presentation 1-Aug-17 9:00pm GMT

    Q2 2017 Regulus Therapeutics Inc Earnings Call

  • Regulus to Present at the 2017 Wedbush PacGrow Healthcare Conference
    PR Newswire8 days ago

    Regulus to Present at the 2017 Wedbush PacGrow Healthcare Conference

    Regulus Therapeutics Inc. (RGLS) is a clinical stage biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs.  Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a rich intellectual property estate to retain its leadership in the microRNA field.  Regulus is advancing several programs in renal, hepatic and central nervous systems diseases. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements.

  • Associated Press15 days ago

    Regulus reports 2Q loss

    The San Diego-based company said it had a loss of 41 cents per share. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was ...